Idea or Concept
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
FDA updates Boston Scientific’s Accolade pacemaker recall, reporting 832 injuries
United States Food and Drug Administration, Mental Recall, Preventive monitoring, trauma qualifier, Medical Devices, Artificial cardiac pacemaker
Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care
Patient-centered epilepsy care, Holistic epilepsy management, Quality of life in epilepsy, Empowering epilepsy patients, Multidisciplinary epilepsy treatment, Epilepsy patient experiences, Comprehensive epilepsy support
Eli Lilly makes Zepbound vials cheaper for self-paying patients
self-paying, Eli, Eli Lilly, Prices, Monthly (qualifier value), Dosage, 7.5 mg, 10 mg
Lilly lowers price of Zepbound vials, launches new doses
Eli Lilly, Dosage, Prices, Affordability, Obesity
Hims eyes growth in its weight loss business, despite end of semaglutide shortage
semaglutide, weight loss business, United States Food and Drug Administration, Growth, Hims
Pfizer taps former FDA drug chief Cavazzoni as new CMO
United States Food and Drug Administration, Pfizer, Cavazzoni, Center for Drug Evaluation and Research, Appointments, President brand of dental material
CDC Vaccine Advisory Committee Meeting Postponed Following RFK Jr.’s Confirmation as HHS Secretary
ACIP, CDC, vaccine recommendations, Robert F. Kennedy Jr., HHS, postponement, public health, immunization policy
Supernus Pharmaceuticals’ Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, clinical trial failure, stock decline, placebo effect
Solid Biosciences’ DMD Gene Therapy Shows Promising Early Results, Driving Stock Surge
Duchenne muscular dystrophy (DMD), gene therapy, SGT-003, microdystrophin, clinical trial, stock surge, Solid Biosciences